Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL8688308 | 0.87 | REN (0.53) | RENKDM4ECYP1A2POLBCYP2C19 | |
| SCHEMBL1144754 | 0.80 | REN (1.00) | REN | |
| SCHEMBL1144061 | 0.79 | CYP1A2 (0.67) | RENKDM4EATML3MBTL1CYP1A2 | |
| SCHEMBL22443294 | 0.78 | KDM4E (0.52) | RENKDM4EATML3MBTL1POLB | |
| SCHEMBL15303882 | 0.76 | RECQL (0.45) | RENKDM4EATML3MBTL1CYP1A2 | |
| SCHEMBL16053883 | 0.76 | REN (0.46) | RENKDM4EPOLB | |
| SCHEMBL1144739 | 0.76 | REN (1.00) | REN | |
| SCHEMBL1144901 | 0.75 | REN (0.69) | REN | |
| Trifluoroacetic Acid SCHEMBL1144906 | 0.75 | REN (0.88) | REN | |
| SCHEMBL1144414 | 0.74 | KDM4E (0.52) | RENKDM4EATML3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247575-B1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-03-23 | — | — | EP | disclosed |
| US-8211885-B2 | Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2012-07-03 | — | — | US | disclosed |
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
| EP-2247575-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009095163-A2 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039830-A1 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, ACE, PM20D2 | REN 1/4885KDM4E 958/4885ATM 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.